New Study From Researchers At Cleveland Clinic Florida Points To Novel Drug Target For Treating COVID-19 Virus

Researchers from Cleveland Clinic’s Florida Research and Innovation Center (FRIC) have identified a potential new target for anti-COVID-19 therapies. Their findings were published in Nature Microbiology.

Led by FRIC scientific director Dr. Michaela Gack, the team discovered that a coronavirus enzyme called PLpro (papain-like protease) blocks the body’s immune response to the infection. More research is necessary, but the findings suggest that therapeutics that inhibit the enzyme may help treat COVID-19.

“SARS-CoV-2 — the virus that causes COVID-19 — has evolved quickly against many of the body’s well-known defense mechanisms,” Gack said. “Our findings, however, offer insights into a never-before characterized mechanism of immune activation and how PLpro disrupts this response, enabling SARS-CoV-2 to freely replicate and wreak havoc throughout the host. We discovered that inhibiting PLpro may help rescue the early immune response that is key to limiting viral replication and spread.”

One of the body’s frontline immune defenses is a class of receptor proteins, including one called MDA5, that identify invaders by foreign patterns in their genetic material. When the receptors recognize a foreign pattern, they become activated and kick-start the immune system into antiviral mode. This is done in part by increasing the downstream expression of proteins encoded by interferon-stimulated genes (ISGs).

In this study, Gack and her team identified a novel mechanism that leads to MDA5 activation during virus infection. They found that ISG15 must physically bind to specific regions in the MDA5 receptor — a process termed ISGylation — in order for MDA5 to effectively activate and unleash antiviral actors against invaders. They showed that ISGylation helps to promote the formation of larger MDA5 protein complexes, which ultimately results in a more robust immune response against a range of viruses.

“While discovery of a novel mechanism of immune activation is exciting on its own,” Gack said, “we also discovered a bit of bad news, which is that SARS-CoV-2 also understands how the mechanism works, considering it has already developed a strategy to block it.”

The research team shows that the coronavirus enzyme PLpro physically interacts with the receptor MDA5 and inhibits the ISGylation process.

“We’re already looking forward to the next phase of study to investigate whether blocking PLpro’s enzymatic function, or its interaction with MDA5, will help strengthen the human immune response against the virus,” Gack said. “If so, PLpro would certainly be an attractive target for future anti-COVID-19 therapeutics.”

Postdoctoral fellow Dr. GuanQun “Leo” Liu, a member of Gack’s laboratory at the FRIC, is the lead author on the study, which was supported by the National Institutes of Health. The FRIC — which complements and expands research underway at Cleveland Clinic’s Lerner Research Institute and Cleveland Clinic Florida’s five regional hospitals — is closely integrated with the Global Center for Pathogen Research & Human Health.

The Cleveland Clinic Florida region is a nonprofit, multi-specialty healthcare provider that integrates clinical and hospital care with research and education.

Physicians at the Cleveland Clinic are experts in the treatment of complex conditions that are difficult to diagnose.

The Florida region now includes Cleveland Clinic Indian River Hospital, Cleveland Clinic Martin Health and Cleveland Clinic Weston Hospital, with five hospitals and numerous outpatient centers in Broward, Palm Beach, Martin and St. Lucie counties.

For more information, visit www.clevelandclinicflorida.org.

LEAVE A REPLY

Please enter your comment!
Please enter your name here